Apyx Medical +22% on FDA Body Contouring Clearance; Rashi Peripherals Posts Record Returns on 62% Revenue Surge

The Quick Take

• Apyx Medical (APYX) posts 22% revenue growth, capitalizing on expanded FDA clearance and growing body contouring demand while reaffirming full-year guidance
• Rashi Peripherals (NSE:RPTECH) reports 62% revenue surge in Q1 FY27 with record ROCE and ROE, driven by strong demand and strategic expansion in India's technology distribution market
• The pair illustrates a global medtech/tech-distribution convergence story: Apyx monetizing FDA-cleared aesthetic device expansion in the US while Rashi captures India's rapid tech hardware demand wave

Two distinct but thematically linked companies — a US medical device maker riding an aesthetic medicine approval wave and an Indian technology distributor capitalizing on domestic tech demand — both reported strong Q2 2026 results that illustrate the breadth of the current earnings upcycle. Apyx Medical Corp (APYX) reported 22% revenue growth in Q2 2026, benefiting from expanded FDA clearance for its energy-based surgical platform in body contouring procedures and reaffirming its full-year guidance despite a modest gross margin step-down from product mix.

Apyx's body contouring market opportunity has been significantly expanded by its FDA clearance for new indications, allowing the company to address a larger addressable patient population across aesthetic surgery and minimally invasive body sculpting procedures. The company's Renuvion device has established a clinical differentiation position in the subdermal coagulation space, which has been validated by strong procedure volume growth across its key cosmetic surgery center accounts.

Rashi Peripherals Ltd (NSE:RPTECH) delivered a 62% revenue surge in Q1 FY27, achieving record returns on capital employed (ROCE) and return on equity (ROE) as it benefited from India's accelerating demand for personal computers, gaming hardware, AI workstation components, and enterprise networking equipment. The company's strategic expansion into higher-value product categories — including AI inference hardware and cloud infrastructure components — is driving margin improvement alongside top-line growth. Together, APYX and RPTECH demonstrate that specialized distribution and device makers with clear demand tailwinds (FDA-cleared US aesthetics, Indian tech infrastructure) are producing outsized returns even within a broadly strong earnings environment.

Synthesized from 2 sources.